Phase 3 Triple Negative Clinical Trials

3 recruitingPhase 3

What is a Phase 3 trial?

Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.

Showing 1–3 of 3 trials

Recruiting

Phase 3

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Triple Negative Breast Neoplasms

Merck Sharp & Dohme LLC1,000 enrolled257 locationsNCT06841354

Recruiting

Phase 3

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms

Merck Sharp & Dohme LLC2,400 enrolled268 locationsNCT06966700

Recruiting

Phase 3

PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

Triple Negative Breast Cancer(TNBC)

Biotheus Inc.360 enrolled70 locationsNCT06419621